FCRL2 Up (Gene Set)

Analyze

Playbook Workflow Builder
Playbook Workflow Builder: Gene Set Enrichment

Perform Gene Set Enrichment with this gene set against Common Fund program's gene sets, identifying significant overlaps using a pre-built PWB workflow. Run the workflow with FCRL2 Up.

GeneSetCart
GeneSetCart

GeneSetCart helps you to fetch gene sets from various data sources, augment, combine with set operations, visualize and analyze these gene sets in a single session. Start a new session with FCRL2 Up.

CFDE-GSE
CFDE Gene Set Enrichment (GSE)

CFDE-GSE illuminates connections between the input gene set and various CF gene sets that overlap with the queried gene set. Query CFDE-GSE with FCRL2 Up.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with FCRL2 Up.

Results found

Linked to

 

Label

Description

 

Gene

ENSG00000153560 - upstream binding protein 1

Gene

ENSG00000068796 - kinesin family member 2A

Gene

ENSG00000170099 - serpin family A member 6

Gene

ENSG00000115263 - glucagon

Gene

ENSG00000005102 - mesenchyme homeobox 1

Gene

ENSG00000107779 - bone morphogenetic protein receptor type 1A

Gene

ENSG00000008710 - polycystin 1, transient receptor potential channel interacting

Gene

ENSG00000174775 - HRas proto-oncogene, GTPase

Gene

ENSG00000184838 - proline rich 16

  • Gene

    ENSG00000153560 - upstream binding protein 1


  • Gene

    ENSG00000068796 - kinesin family member 2A


  • Gene

    ENSG00000170099 - serpin family A member 6


  • Gene

    ENSG00000115263 - glucagon


  • Gene

    ENSG00000005102 - mesenchyme homeobox 1


  • Gene

    ENSG00000107779 - bone morphogenetic protein receptor type 1A


  • Gene

    ENSG00000008710 - polycystin 1, transient receptor potential channel interacting


  • Gene

    ENSG00000174775 - HRas proto-oncogene, GTPase


  • Gene

    ENSG00000184838 - proline rich 16

  • DISPLAY PER PAGE
    This repository is under review for potential modification in compliance with Administration directives.